ALLMedicine™ Prostate Cancer Staging Center

Mar 5th, 2021 - There has been a growing body of evidence highlighting the improved sensitivity and specificity for prostate specific membrane antigen (PSMA) positron emission tomography (PET) in advanced prostate cancer imaging. We aimed to assess prostate cance...

Feb 9th, 2021 - In May 2012 the US Preventive Task Force issued a 'D' recommendation against routine PSA-based early detection of prostate cancer. This recommendation was implemented progressively in our health system. The aim of this study is to define its impac...

Oct 29th, 2020 - Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used in managing and staging prostate cancer, but can identify other non-prostate pathology. We present the first reported case where small bo...

Sep 3rd, 2020 - The isotope bone scan (IBS) is the gold-standard imaging modality for detecting skeletal metastases as part of prostate cancer staging. However, its clinical utility for assessing skeletal metastatic burden is limited due to the need for subjectiv...

Jul 22nd, 2020 - Prostate-specific membrane antigen (PSMA) positron emission tomography (PSMA-PET) improves prostate cancer staging. Intraprostatic PSMA intensity may predict clinically relevant oncological outcomes. The aim of this study was to investigate the re...

Dec 31st, 2017 - This guideline addresses prostate cancer early detection for the purpose of reducing prostate cancer mortality with the intended user as the urologist. This document does not make a distinction between early detection and screening for prostate ca.

Sep 27th, 2017 - Two phase III trials have compared ADT alone versus ADT plus abiraterone and prednisolone in men with metastatic, hormone-naive disease. The LATITUDE trial included men with high risk metastatic disease.

Jun 9th, 2017 - ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naïve men with castration-resi.

Jun 9th, 2017 - This PCO addresses the use of the second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only biochemical evidence of CRPC to having documented metastases but.

Mar 31st, 2017 - These guidelines for the management of localized prostate cancer are structured first, to provide a clinical framework stratified by cancer severity to facilitate care decisions and second, to guide the specifics of implementing the selected manag.

Mar 5th, 2021 - There has been a growing body of evidence highlighting the improved sensitivity and specificity for prostate specific membrane antigen (PSMA) positron emission tomography (PET) in advanced prostate cancer imaging. We aimed to assess prostate cance...

Feb 9th, 2021 - In May 2012 the US Preventive Task Force issued a 'D' recommendation against routine PSA-based early detection of prostate cancer. This recommendation was implemented progressively in our health system. The aim of this study is to define its impac...

Nov 1st, 2020 - NEW YORK (Reuters Health) - A pretreatment, predictive staging system for nonmetastatic prostate cancer, based on data analysis rather than expert consensus, promises to improve on existing risk-stratification systems, according to an internationa...

Nov 1st, 2020 - NEW YORK (Reuters Health) - A pretreatment, predictive staging system for nonmetastatic prostate cancer, based on data analysis rather than expert consensus, promises to improve on existing risk-stratification systems, according to an internationa...

Oct 29th, 2020 - Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used in managing and staging prostate cancer, but can identify other non-prostate pathology. We present the first reported case where small bo...

Nov 1st, 2020 - NEW YORK (Reuters Health) - A pretreatment, predictive staging system for nonmetastatic prostate cancer, based on data analysis rather than expert consensus, promises to improve on existing risk-stratification systems, according to an internationa...

Nov 1st, 2020 - NEW YORK (Reuters Health) - A pretreatment, predictive staging system for nonmetastatic prostate cancer, based on data analysis rather than expert consensus, promises to improve on existing risk-stratification systems, according to an internationa...